JD Supra

No (More) Bites at the mRNA Apple: Pfizer and BioNTech Seek Declaratory Judgment of Noninfringement Relating to Their COVID-19 Vaccine in New Suit

On 25 July 2022, BioNTech SE and BioNTech Manufacturing GmbH (collectively, BioNTech) and Pfizer Inc. (Pfizer) (collectively, Plaintiffs) filed suit 1 in the District of Massachusetts against CureVac ...
JD Supra

Moderna Litigation Against BioNTech and Pfizer Stayed Pending IPR

We previously reported on the litigation brought by ModernaTX, Inc. and Moderna US, Inc. (collectively, “Moderna”) against BioNTech SE, BioNTech Manufacturing GmbH, BioNTech US Inc. (collectively, ...
FiercePharma

BioNTech to wind down cell therapy manufacturing in Maryland, lay off 63 as it ends development of CAR-T drug in testicular cancer

Following a disappointing performance from the company’s CAR-T candidate in an early-stage cancer trial, BioNTech is winding down cell therapy manufacturing at its inaugural U.S. plant. BioNTech will ...
Seeking Alpha

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended form A hearing on infringement of EP ...
Reuters

BioNTech aims to start mRNA vaccine output in Rwanda in 2025

NAIROBI, Dec 18 (Reuters) - COVID-19 vaccine maker BioNTech (22UAy.DE), opens new tab aims to start production at its mRNA vaccine factory site in Rwanda in 2025, company officials said on Monday, the ...